Few Residents Choose Pulmonary/Critical Care

BY DOUG BRUNK

San Diego Bureau

SEATTLE — Few internal medicine residents show interest in pursuing a career in pulmonary and critical care medicine, Scott Lorin, M.D., reported at a press briefing during the annual meeting of the American College of Chest Physicians.

In fact, there are only two subspecialties-endocrinology and rheumatologythat are chosen less often by internal med-

icine residents, according to a survey conducted by Dr. Lorin of the department of medicine, Mount Sinai School of Medicine, New York, and his associates.

In 2002, they surveyed 178 internal medicine and combined internal medicine/pediatric residents about their attitudes and perceptions regarding pulmonary and critical care medicine training. The residents, whose average age was 29 years, were from Mount Sinai; the Medical University of South Carolina, Charleston; and the University of North Carolina at Chapel Hill.

Although 41% reported that they "seriously considered" a fellowship in pulmonary and critical care medicine at some point during their residency, only 3.4% actually chose to pursue a fellowship in the

The five most common factors that would attract the residents to a fellowship in the field were intellectual stimulation (69%), opportunities to manage critically ill patients (51%), application of complex

physiologic principles (45%), number of procedures performed (31%), and academically challenging rounds (29%).

The five most common factors that would dissuade them from entering the field were a perceived lack of leisure time (54%), stress among faculty/fellows (45%), management responsibilities for chronically ill patients (30%), poor match of career with resident personality (24%), and treatment of pulmonary diseases (16%).

"If they had a positive perception of faculty and fellows, they wanted to go into pulmonary and critical care medicine," Dr. Lorin said.

The survey also showed that few respondents had an interest in bench research. "The majority wanted to go into clinical practice," he said.

References: 1. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192-199. 2. Roth T, Roehrs T, Vogel G. Zolpidem in the treatment of transient insomnia: a double-blind, randomized comparison with placebo. Sleep. 1995;18:246-251. 3. Elie R, Rüther E, Farr I, Emilien G, Salinas E, for the Zaleplon Clinical Study Group. Sleep latency is shortened during 4 weeks of treatment with zaleplon, a novel nonbenzodiazepine hypnotic. J Clin Psychiatry. 1999;60:536-544. 4. AMBIEN Prescribing Information, Sanofi-Synthelabo Inc. 5. Office of Applied Studies, Drug Abuse Warning Network (DAWN). Substance Abuse and Mental Health Services Administration, US Department of Health and Human Services. Reports & tables from DAWN emergency department component. Table 2.6.0. Available at: http://dawninfo.samhsa.gov/pubs_94_02/edpubs/2002final/files/PubTablesCh2.xls. Accessed December 9, 2003. 6. Hajak G, Müller WE, Wittchen HU, Pittrow D, Kirch W. Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data. Addiction. 2003;98:1371-1378. 7. IMS Health, National Prescription Audit Plus, December 2003.



BRIEF SUMMARY

INDICATIONS AND USAGE

a) is indicated for the short-ter

Ambien has been shown to decrease sleep latency and increase the duration of sleep for up to 35 days in controlled clinical studies.
Hypnotics should generally be limited to 7 to 10 days of use, and reevaluation of the patient is recommended if they are to be taken for more than 2 to 3 weeks. Ambien should not be prescribed in quantities exceeding a 1-month supply (see Warnings).

CONTRAINDICATIONS

WARNINGS

Since sleep disturbances may be the presenting manifestation of a physical and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit and/or psychiatric disorder, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7 to 10 days of treatment may indicate the presence of a primary psychiatric and/or medical lilness which should be evaluated. Worsening of insomnia or the emergence of new thinking or behavior abnormalities may be the consequence of an unrecognized psychiatric or physical disorder. Such findings have emerged during the course of treatment with sedative/hyponotic drugs, including Ambien, Because some of the important adverse effects of Ambien appear to be dose related (see Precautions and Dosage and Administration), it is important to use the smallest possible effective dose, especially in the delaty. A variety of abnormal thinking and behavior changes have been reported to occur in association with the use of sedative/hyponotics. Some of these changes may be characterized by decreased inhibition (eg. aggressiveness and extroversion that seemed out of character), similar to effects produced by alcohol and other CNS depressants. Other reported behavioral changes have included bizarre behavior, agitation, hallucinations, and depersonalization. Annesia and other neuropsychiatric symptoms may occur unpredictably. In primarily depressed patients, worsening of depression, including suicidal thinking, has been reported in association with the use of sedative/hyponics. It can rarely be determined with certainty whether a particular instance of the abnormal behaviors Isted above is drug induced, spontaneous in origin, or a result of an underfying psychiatric or physical disorder. Nonetheless, the emergence of any new behavioral sign or symptom of occorer requires careful and immediate evaluation.
Following the rapid dose decrease or abrupt discontinuation of sedative/hyponotics, there have been reports of signs and symptoms similar to those associated with withdrawal from other CNS-depressant drugs less Drug Abuse and Dependence).
Ambien, like other sed

ated with withdrawal from other CNS-depressant drugs (see *Drug Abuse and Dependence*).

Ambien, like other sedative/hypnotic drugs, has CNS-depressant effects, but the rapid onset of action, Ambien should only be ingested immediately prior to going to bed. Patients should be cautioned against engaging in hezardous occupations requiring complete mental alertness or motor coordination such as operating machinery or driving a motor vehicle after ingesting the drug, including potential impairment of the performance of such activities that may occur the day following ingestion of Ambien. Ambien showed additive effects when combined with action land should not be taken with action. Patients should also be cautioned about possible combined effects with other CNS-depressant drugs. Dosage adjustments may be necessary when Ambien is administered with such agents because of the potentially additive effects.

PRECAUTIONS

Use in the elderly and/or debilitated patients: Impaired motor and/or cognitive performance after repeated exposure or unusual sensitivity to sedative/hypnotic drugs is a concern in the treatment of elderly and/or debilitated patients. Therefore, the recommended Ambien dosage is 5 mg in such patients (see Dosage and Administration) to decrease the possibility of side effects. These patients should be dosely monitored.

Dosage and Administration to decrease the possioniny of side enricets. These patients should be closely monitored.

Use in patients with concomitant illness: Clinical experience with Ambien in patients with concomitant systemic illness is limited. Caution is advisable in using Ambien in patients with diseases or conditions that could affect metabolism or hemodynamic responses. Although studies did not reveal respiratory depressant effects at hypnotic doses of Ambien in normals or in patients with mild to moderate chronic obstructive pulmonary disease (COPD), a reduction in the Total Arousal Index together with a reduction in lowest oxygen saturation and increase in the times of oxygen desaturation below 80% and 90% was observed in patients with mild-to-moderate sleep apnea when treated with Ambien 10 mg) when compared to placebo. However, precautions should be observed if Ambien is prescribed to patients with compromised respiratory function, since sedative/hypnotics have the capacity to depress respiratory function, since sedative/hypnotics have the capacity to depress respiratory direction, since sedative/hypnotics have the capacity to depress respiratory direction and the pre-existing respiratory insufficiency, most of which involved patients with pre-existing respiratory insufficiency, most of which involved patients with pre-existing respiratory insufficiency, most of which involved patients should be closely monitored (see Pharmacokinetics). A study in subjects with hepatic impairment did reveal prolonged elimination in this group; therefore, treatment should be instated with 5 mg in patients with hepatic compromise, and they should be closely monitored.

These, and they should be closely minitorieu. Wes in depression: As with other sedative/hypnotic drugs, Ambien should be administered with caution to patients exhibiting signs or symptoms of depression. Suicidal tendencies may be present in such patients and protective measures may be required. Intentional overdosage is more common in this group of patients; therefore, the least amount of drug that is feasible should be prescribed for the patient at any one time.

Information for patients: Patient information is printed in the complete prescribing information.

Laboratory tests: There are no specific laboratory tests recommended.

urug interactions CMS-active drugs: Ambien was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs. A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharma-codynamics of zolpidem. Imipramine in combination with zolpidem produced no codynamics of zolpidem. Impramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of impramine, but there was an additive effect of decreased alertness. Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance. The lack of a drug interaction following single-dose administration does not predict a lack following chronic administration. An additive effect on psychomotor performance between alcohol and zolpidem was demonstrated.

an was cerioristated. A single-dose interaction study with zolpidem 10 mg and fluoxetine 20 mg at teady-state levels in male volunteers did not demonstrate any clinically signifi-ant pharmacokinetic or pharmacodynamic interactions. When multiple doses of olpidem and fluoxetine at steady-state concentrations were evaluated in healthy zolpidem and fluoxetine at steady-state concentrations were evaluated in healthy females, the only significant change was a 17% increase in the zolpidem half-life. There was no evidence of an additive effect in psychomotor performance. Following five consecutive nightly doses of zolpidem 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female vol-

s), zobidem \mathbb{Q}_{ms} was significantly higher (43%) and \mathbb{T}_{ms} was significantly sed (53%). Pharmacokinetics of sertraline and N-desmethylsertraline were ted by zobidem.

e the systematic evaluations of Ambien in combination with other CNS-

active drugs have been limited, careful consideration should be given to the pharmacology of any CNS-active drug to be used with zolpidem. Any drug with CNS-depressant effects could potentially enhance the CNS-depressant effects of

Drugs that affect drug metabolism via cytochrome P450: A randomized, double-blind, crossover interaction study in ten healthy volunteers between itraconazole (200 mg once daily for 4 days) and a single dose of zolpidem (10 mg) given 5 hours after the last dose of itraconazole resulted in a 34% increase in AUC_{p−∞} of zolpidem. There were no significant pharmacodynamic effects of zolpidem on subjective drowsiness, postural sway, or psychomotor performance. A randomized, placebo-controlled, crossover interaction study in eight healthy

A manufacture, precure-controlled, crossover interaction study in eight healthy female volunteers between 5 consecutive daily doses of rifampin (600 mg) and a single dose of zolpidem (20 mg) given 17 hours after the last dose of rifampin showed significant reductions of the AUC (–73%), C._{max}. (–58%), and T.₁₅. (–58%) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem.

Other drugs: A study involving cimetidine/zolpidem and ranitidine/zolpidem combinations revealed no effect of either drug on the pharmacokinetics or pharmacokinetics or pharmacokinetics or pharmacokinetics or pharmacokinetics. comminators revealed to elect or level of the plantacount existing macodynamics of zolpidem. Zolpidem had no effect on digoxin kinetics and did not affect prothrombin time when given with warfarin in normal subjects. Zolpidem's sedative/hypnotic effect was reversed by flumasenil; however, no significant alterations in zolpidem pharmacokinetics were found.

Drug/Laboratory test interactions: Zolpidem is not known to interfere with commonly employed clinical laboratory tests. In addition, clinical data indicate that zolpidem does not cross-react with benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screens.

Carcinogenesis, mutagenesis, impairment of fertility Carcinogenesis: Zolpidem was administered to rats and mice for 2 years at dietary dosages of 4, 18, and 80 mg/kg/day, In mice, these doses are 26 to 520 times or 2 to 35 times the maximum 10-mg human dose on a mg/kg or mg/m³ basis, respectively. In rats these doses are 45 to 876 times of 6 to 115 times the basis, respectively. In rats these doses are 43 to 876 times or 6 to 115 times time aximum 10-mg human dose on a mg/kg or mg/m² basis, respectively. No evidence of carcinogenic potential was observed in mice. Renal liposarcomas were seen in 4/100 rats (3 males, 1 female) receiving 80 mg/kg/day and a renal lipoma was observed in one male rat at the 18 mg/kg/day dose. Incidence rates of lipoma and liposarcoma for zolpidem were comparable to those seen in historic controls and the tumor findings are thought to be a spontaneous occurrence.

Mutagenesis: Zolpidem did not have mutagenic activity in several tests includ-ing the Ames test, genotoxicity in mouse lymphoma cells in vitro, chromosomal aberrations in cultured human lymphocytes, unscheduled DNA synthesis in rat hepatocytes in vitro, and the micronucleus test in mice.

Impairment of fertility: In a rat reproduction study, the high dose (100 mg base)kg) of zolpidem resulted in irregular estrus cycles and prolonged precoital intervals, but there was no effect on male or female fertility after daily oral doses of 4 to 100 mg base/kg or 5 to 130 times the recommended human dose in mg/m. No effects on any other fertility parameters were noted.

Pregnancy
Teratogenic effects: Category B. Studies to assess the effects of zolpidem on
human reproduction and development have not been conducted.
Teratology studies were conducted in rats and rabbits.
In rats, adverse maternal and fetal effects occurred at 20 and 100 mg base/kg
and included dose-related maternal lethargy and ataxia and a dose-related trend
to incomplete ossification of fetal skull bones.
In rabbits, dose-related maternal sedation and decreased weight gain
occurred at all doses tested. At the high dose, 16 mg base/kg, there was an
increase in postimplantation fetal loss and underossification of sternebrae in
viable fetuses.

viable fetuses.

This drug should be used during pregnancy only if clearly needed.

Nonteratogenic effects: Studies to assess the effects on children whose mothers took zolpidem during pregnancy have not been conducted. However, children born of mothers taking sedative/hypontic drugs may be at some risk for with drawal symptoms from the drug during the postnatal period. In addition, neonatal flaccidity has been reported in infants born of mothers who received sedative/hypnotic drugs during pregnancy.

Labor and delivery: Ambien has no established use in labor and delivery.

Nursing mothers: Studies in lactating mothers indicate that between 0.004 and 0.019% of the total administered dose is excreted into milk, but the effect of zolpidem on the infant is unknown.

The use of Ambien in nursing mothers is not recommended.

Pediatric use: Safety and effectiveness in pediatric patients below the age of 18 have not been established.

nave not been established.

Geriatric use: A total of 154 patients in U.S. controlled clinical trials and 897 patients in non-U.S. clinical trials who received zolpidem were >60 years of age. For a pool of U.S. patients receiving zolpidem at doese of >61 om gor placebo, there were three adverse events occurring at an incidence of at least 3% for zolpidem and for which the zolpidem indedence was at least twice the placebo incidence (ie, they could be considered drug related).

and the first state of the stat			
Adverse Event	Zolpidem	Placebo	
Dizziness	3%	0%	
Drowsiness	5%	2%	
Diarrhea	3%	1%	

A total of 30/1,959 (1.5%) non-U.S. patients receiving zolpidem reported falls, including 28/30 (93%) who were ≥70 years of age. Of these 28 patients, 23 (82%) were receiving zolpidem doses >10 mg. A total of 24/1,956 (1.2%) non-Loss patients receiving zolpidem reported confusion, including 18/24 (75%) who were ≥70 years of age. Of these 18 patients, 14 (78%) were receiving zolpidem doses >10 mg.

>10 mg.

ADVERSE REACTIONS

Associated with discontinuation of treatment: Approximately 4% of 1,701 patients who received zolpidem at all doses (1.25 to 90 mg) in U.S. premarketing clinical trials discontinued treatment because of an adverse clinical event. Events most commonly associated with discontinuation from U.S. trials were daytime drows/ness (0.5%), dizziness (0.4%), headache (0.5%), nausea (0.6%), and vomitation of the control o

ing (0.5%). Approximately 4% of 1,959 patients who received zolpidem at all doses (1 to 50 mg) in similar foreign trials discontinued treatment because of an adverse event. Events most commonly associated with discontinuation from these trials

were dyytime drowscinnen (1,1%), drziznesski vertige (0.8%), amnesia (0.5%), nau-sea (0.5%), headach (0.4%), and falls (0.4%). Data fron a clinical study in which selective serotonin reuptake inhibitor-(SSRI) treated patients were given copiedem revealed that four of the seven dis-continuations during double-blind treatment with zolpidem (n=95) were associ-

Incidence in controlled clinical trials Most commonly observed adverse events in controlled trials: During short-term treatment (up to 10 nights) with Ambien at doses up to 10 mg, the most com-monly observed adverse events associated with the use of zopidem and seen at statistically significant differences from placebo-treated patients were drowsi-ness (reported by 2% of zolpidem patients), dizziness (1%), and diarrhea (1%). During longer-term treatment (28 to 35 nights) with zolpidem at doses up to 10

Treatment-emergent adverse experiences in placebo-controlled clinical trials: The following are treatment-emergent adverse events from U.S. placebo-controlled clinical trials. Data are limited to data from doses up to and including 10 mg. In short-term trials, events seen in zolpidem patients (n=685) at an incidence equal to 1% or greater compared to placebo (n=473) were: headache (7% vs 6% or placebo), drowsiness (2% vs 0%), dizieness (1% vs 0%), nausea (2% vs 0%), diarrhea (1% vs 0%), and myalgia (1% vs 2%). In long-term clinical trials, events seen in zolpidem patients (n=152) at an incidence of 1% or greater compared to placebo (n=161) were: dry mouth (3% vs 1% for placebo), allergy (4% vs 1%),

back pain (3% vs 2%), influenza-like symptoms (2% vs 0%), chest pain (1% vs 0%), fatigue (1% vs 2%), palpitation (2% vs 0%), headache (13% vs 22%), drowsiness (8% vs 5%), dizziness (5% vs 1%), lethargy (3% vs 1%), drugged feeling (3% vs 0%), lightheadedness (2% vs 1%), abnormal farms (1% vs 0%), amnesia (1% vs 0%), dvspepsia (6% vs 6%), dvslepsia (6% vs 6%), dvs pesia (6% vs 6%), dvs pesia (6% vs 6%), dvs pesia (3% vs 2%), anorexia (1% vs 1%), vomiting (1% vs 1%), infection (1% vs 1%), myalgia (7% vs 7%), arbratigia (4% vs 4%), upper respiratory infection (5% vs 6%), sinusitis (4% vs 2%), pharyngitis (3% vs 1%), rhintitis (1% vs 3%), rash (2% vs 1%), and urinary tract infection (2% vs 2%).

Dose relationship for adverse events: There is evidence from dose comparison trials suggesting a dose relationship for many of the adverse events associated with zolpidem use, particularly for certain CNS and gastrointestinal adverse

events.

Adverse events are further classified and enumerated in order of decreasing frequency using the following definitions: frequent adverse events are defined as those occurring in greater than 1/100 subjects; infrequent adverse events are those occurring in 1/100 to 1/1,000 patients; rare events are those occurring in less than 1/1,000 patients.

Frequent: abdominal pain, abnormal dreams, allergy, amnesia, anorexia, anxiety, arthralgia, asthenia, ataxia, back pain, chest pain, confusion, constipation, depression, diarrhea, diplopia, diziraes, drowainess, drugged feeling, dry mouth, dryspepsia, euphoria, fatigue, headache, hiccup, infection, influenza-like symptoms, insomnia, lethargy, lightheadedness, myaglia, nausea, nervousness, papitation, sepe disorder, vertigo, vision abnormal, vomiting.

palpitation, seep disorder, Vertigo, vision abnormat, vormiting, Infrequent: abnormal hepatic function, aglitation, arthritis, bronchitis, cere-brovascular disorder, coughing, cystitis, decreased cognition, detached, difficul-ty concentrating, dysarthria, dysphagia, dyspnea, edema, emotional lability, eye irritation, eye pain, falling, fever, flatulence, gastroententis, hallucination, hyper-glycemia, hypertension, hypoesthesia, illusion, increased SGPT, increased sveating, leg cramps, malaise, menstrual disorder, migraine, pallor, paresthesia, postural hypotension, pruritus, scleritis, sleeping (after daytime dosing), speech disorder, stupor, syncope, tachyacrdia, taste perversion, thirst, tinnitus, trauma, tremor, urinary incontinence, vaginitis.

disorder, stupor, syncope, tachycardia, taste perversion, thirst, tinnitus, trauma, tremor, urinary incontinence, vaginitis.

Rare: abdominal body sensation, abnormal accommodation, abnormal gait, abnormal thinking, abscess, acne, acute renal fallure, aggressive reaction, allergic reaction, allergy aggravated, altered saliva, anaphylactic shock, anemia, angina pectoris, apathy, appetite increased, arrhythmia, arteritis, arthrosis, bilinchemia, breast fibroadenosis, breast nepolasm, breast pain, bronchospasm, bullous eruption, circulatory failure, conjunctivitis, comeal ulceration, decreased libido, delusion, demental, depersonalization, dermattis, dysphasia, dysuria, enteritis, epistaxis, eructation, esophagospasm, extrasystoles, face edema, feeling strange, flushing, furunculosis, gastritis, glaucoma, gout, hemorrhoids, herpes simplex, herpes zoster, hot flashes, hypercholesteremia, hyperhemoglo-inemia, hypotani, hypoxia, hysteria, impotence, increased alkaline phosphatase, increased BIVI, increased ESR, increased salva, increased SGOT, injection-site inflammation, intestinal obstruction, intoxicated feeling, lacrimation abnormal, larynqtis, leukopenia, hymphadenopathy, macrocytic anemia, manic reaction, micturition frequency, muscle weakness, myocardiai infarction, neuralia, neuris, neuropathy, neurosis, nocturia, ottitis externa, ottitis media, pain, panic attacks, paresis, parosmia, periorbital edema, personality disorder, phlebitis, neuropathy, neurosis, nocturia, ottitis externa, ottitis media, pain, panic attacks, paresis, parosmia, periorbital edema, personality disorder, phlebitis, restless lega, ripors, scalatica, somnambulisms, suicide attempts, tendinist, tenesmus, tetany, thrombosis, tolerance increased, tooth caries, urinary retention, urricaria, varicose veins, ventricular tachycardii, weight decrease, yawning.

DRUG ABUSE AND DEPENDENCE Controlled substance: Schedule IV.

Controlled substance: Schedule IV.

Abuse and dependence: Studies of abuse potential in former drug abusers found that the effects of single doses of zolpidem tartrate 40 mg were similar, but not identical, to diazepam 20 mg, while zolpidem tartrate 10 mg was difficult to distinguish from placebo.

Sedative/hypnotics have produced withdrawal signs and symptoms following abrupt discontinuation. These reported symptoms range from mild dysphoria and insomnia to a withdrawal syndrome that may include abdominal and muscle cramps, vomiting, sweating, tremors, and convulsions. The U.S. clinical trial experience from zolpidem does not reveal any clear evidence for withdrawal syndrome. Nevertheless, the following adverse events included in DSM-III-B criteria for uncomplicated sedative/hypnotic withdrawal were reported at an incrine within 48 hours following last zolpidem treatment fatigue, nausea, flushing lightheadedness, uncontrolled cyving, emessi, stomach cramps, panic attack, nervousness, and abdominal discomfort. Rare post-marketing reports of abuse, dependence and withdrawal have been received.

Individuals with a history of addiction to, or abuse of, drugs or alcohol are at increased risk of habituation and dependence; they should be under careful surveillance when receiving any hypnotic.

increased risk of nantuation and a veillance when receiving any hypnotic.

OVERDOSAGE

OVENDOSAGE
Signs and symptoms: In European postmarketing reports of overdose with zolpidem alone, impairment of consciousness has ranged from somnolence to light
coma, with one case each of cardiovascular and respiratory compromise,
individuals have fully recovered from zolpidem tartrate overdoses up to 400 mg

Recommended treatment: General symptomatic and supportive measures should be used along with immediate gastric lavage where appropriate. Intravenous fluids should be administered as needed. Humazenil may be useful. Respiration, pulse, blood pressure, and other appropriate signs should be monitored and general supportive measures employed. Sedating drugs should be withheld following zolpidem overdosage, Zolpidem is not dialyzable. The possibility of multiple drug ingestion should be considered.

Distributed by:

sanofi~synthelabo

Davisand	A

INDEX OF

ADVERTISERS Actelion Pharmaceuticals US, Inc. 22a-22b, 23 Adams Laboratories, Inc. AstraZeneca Pharmaceuticals LP. 37-38 Seroquel Bertek Pharmaceuticals, Inc. Boehringer Ingelheim Pharmaceuticals, Inc. 6a-6b Bristol-Myers Squibb Medical Imaging, Inc. 62a-62b Forest Pharmaceuticals, Inc. Combunoz Campral 34a-34d Lexapro 66a-66b Fujisawa Healthcare, Inc. 9-10 GlaxoSmithKline Hoffmann-La Roche Inc. Janssen Pharmaceutica Products, L.P. 13-14, 65-66 **Eli Lilly and Company** 24-26

62 Merck & Co., Inc. 14a-14b 54a-54d **Novartis Pharmaceuticals Corporation** 42a-42d Ortho-McNeil Pharmaceutical, Inc. 17-21 70a-70b Corporate Pfizer Inc. Relpax 33-34

50, 50a-50b

38a-38d

57-58

Medpointe Pharmaceuticals

Medtronic MiniMed

Zomig

Rexall Sundown, Inc. Roche Laboratories Inc. Elecsys Sanofi Aventis Ambien 72-74

Santarus, Inc. Zegerid Solvay Pharmaceuticals, Inc. Company AndroGel Takeda Pharmaceuticals America, Inc.

Purdue Pharmaceutical Products L.P.

26a-26b Wyeth Pharmaceuticals Inc. 29-31 Effexor XR